RT Journal Article
SR Electronic
T1 Pharmacokinetics of favipiravir in adults with mild COVID-19 in Thailand
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.09.22271220
DO 10.1101/2022.03.09.22271220
A1 Weerawat Manosuthi
A1 Ing-orn Prasanchaimontri
A1 Suvimol Niyomnaitham
A1 Rujipas Sirijatuphat
A1 Lantharita Charoenpong
A1 Katherine Copeland
A1 Tim R. Cressey
A1 Phongpan Mokmued
A1 Kulkanya Chokephaibulkit
YR 2022
UL http://medrxiv.org/content/early/2022/03/12/2022.03.09.22271220.abstract
AB We assessed the pharmacokinetics of favipiravir (FPV) in adults with symptomatic SARS-CoV-2 infection without pneumonia in Thailand. FPV dosing was 1800 mg twice-daily on day 1, then 800 mg twice-daily for 14 days. Eight subjects (7 female), median (range) age 39 (19-53) years and BMI 27.9 (18.0-33.6) were included. Inter-subject variability was high but all achieved minimum plasma concentrations (Cmin) above EC50 (9.7 mg/L). FPV was well tolerated; 1 subject stopped prematurely due to rash.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTCTR20200514001Funding StatementThis work was supported by the National Research Council of Thailand (Grant Number: 63-088) and the Siriraj Research and Development Fund, Faculty of Medicine Siriraj Hospital, Mahidol University (Grant Number: (IO) R016434001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Siriraj Institutional Review Board (approval no. Si 434/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request.